Health insurance system for hematologic diseases: what should we do?

Health insurance system for hematologic diseases: what should we do?

Korean National Health Insurance (NHI) was introduced in 1963 and became a nationwide health insurance after several law reforms in 1988. As a result of nationalization, coverage has expanded, and its service level has greatly improved since 1998 [1]. However, several diagnostic and therapeutic modalities for rare, incurable diseases such as malignant hematologic diseases are excluded from the ...

Mental Health What Do We Know? What Should We Do?

Multimorbidity: What do we know? What should we do?

Multimorbidity, which is defined as the co-occurrence of two or more chronic conditions, has moved onto the priority agenda for many health policymakers and healthcare providers. Patients with multimorbidity are high utilizers of healthcare resources and are some of the most costly and difficult-to-treat patients in Europe. Preventing and improving the way multimorbidity is managed is now a key...

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

What should we do next for MT system development?

Machine translation (MT) research and development began at the end of 1950’s when not only natural language processing (NLP) technology but also linguistic theory was at a primitive level. Given the restricted memory sizes and computing power at that time, MT presented one of the most difficult and challenging research themes of the day. Thus. MT researchers and developers were forgiven when th...